Possible neuroprotective effect of brimonidine in a mouse model of ischaemic optic neuropathy

Clinical and Experimental Ophthalmology

Volumn 37, Issue 7, 2009, Pages 718-729

  Goldenberg Cohen, Nitza ^a,b   Dadon Bar El, Shimrit ^b,c   Hasanreisoglu, Murat ^d   Avraham Lubin, Bat Chen R ^b   Dratviman Storobinsky, Olga ^b,c   Cohen, Yoram ^e   Weinberger, Dov ^b,d  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BAR ILAN UNIVERSITY   (Israel)

^d RABIN MEDICAL CENTER   (Israel)

^e SHEBA MEDICAL CENTER   (Israel)

Author keywords

Anterior ischaemic optic neuropathy in rodents (rAION); Brimonidine; Gene expression; Mouse model; Neuroprotection

Indexed keywords

ALPHAGAN P; BRIMONIDINE; COPPER ZINC SUPEROXIDE DISMUTASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIDERMAL GROWTH FACTOR; GLUTATHIONE PEROXIDASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PIGMENT EPITHELIUM DERIVED FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; ISCHEMIC OPTIC NEUROPATHY; MALE; MOUSE; NERVOUS TISSUE; NEUROPROTECTION; NONHUMAN; OPTIC NERVE; OXIDATIVE STRESS; RETINA GANGLION CELL;

ANIMALS; DISEASE MODELS, ANIMAL; EYE PROTEINS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION; GLUTATHIONE PEROXIDASE; HEME OXYGENASE-1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED C57BL; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE TYPE III; OPTIC NEUROPATHY, ISCHEMIC; OXIDATIVE STRESS; QUINOXALINES; RECEPTOR PROTEIN-TYROSINE KINASES; RETINAL GANGLION CELLS; RETINAL NEOVASCULARIZATION; SERPINS; SUPEROXIDE DISMUTASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70350151551     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2009.02108.x     Document Type: Article

References (51)

1. Bernstein SL, Guo Y, Slater BJ, Puche A, Kelman SE. Neuron stress and loss following rodent anterior ischemic optic neuropathy in double-reporter transgenic mice. Invest Ophthalmol Vis Sci 2007, 48:2304-10.
2. Bernstein SL, Guo Y, Kelman SE, Flower RW, Johnson MA. Functional and cellular responses in a novel rodent model of anterior ischemic optic neuropathy. Invest Ophthalmol Vis Sci 2003, 44:4153-62.
3. Goldenberg-Cohen N, Guo Y, Margolis F, Cohen Y, Miller NR, Bernstein SL. Oligodendrocyte dysfunction after induction of experimental anterior optic nerve ischemia. Invest Ophthalmol Vis Sci 2005, 46:2716-25.
4. Aktas Z, Gurelik G, Akyurek N, Onol M, Hasanreisoglu B. Neuroprotective effect of topically applied brimonidine tartrate 0.2% in endothelin-1-induced optic nerve ischaemia model. Clin Experiment Ophthalmol 2007, 35:527-34.
5. Li Y, Schlamp CL, Nickells RW. Experimental induction of retinal ganglion cell death in adult mice. Invest Ophthalmol Vis Sci 1999, 40:1004-8.
6. Bakalash S, Kipnis J, Yoles E, Schwartz M. Resistance of retinal ganglion cells to an increase in intraocular pressure is immune-dependent. Invest Ophthalmol Vis Sci 2002, 43:2648-53.
7. Levin LA. Intrinsic survival mechanisms for retinal ganglion cells. Eur J Ophthalmol 1999, 9(1):S12-16. Suppl.
8. Bakalash S, Kessler A, Mizrahi T, Nussenblatt R, Schwartz M. Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma. Invest Ophthalmol Vis Sci 2003, 44:3374-81.
9. Levin LA. Retinal ganglion cells and neuroprotection for glaucoma. Surv Ophthalmol 2003, 48(1):S21-4. Suppl.
10. Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging 1998, 12:225-41.
11. Aviles-Trigueros M, Mayor-Torroglosa S, Garcia-Aviles A. Transient ischemia of the retina results in massive degeneration of the retinotectal projection: long-term neuroprotection with brimonidine. Exp Neurol 2003, 184:767-77.
12. Lafuente Lopez-Herrera MP, Mayor-Torroglosa S, Miralles de Imperial J, Villegas-Perez MP, Vidal-Sanz M. Transient ischemia of the retina results in altered retrograde axoplasmic transport: neuroprotection with brimonidine. Exp Neurol 2002, 178:243-58.
13. Vidal-Sanz M, Lafuente MP, Mayor-Torroglosa S, Aguilera ME, Miralles de Imperial J, Villegas-Perez MP. Brimonidine's neuroprotective effects against transient ischaemia-induced retinal ganglion cell death. Eur J Ophthalmol 2001, 11(2):S36-40. Suppl.
14. Gao H, Qiao X, Cantor LB, WuDunn D. Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch Ophthalmol 2002, 120:797-803.
15. Levkovitch-Verbin H, Harris-Cerruti C, Groner Y, Wheeler LA, Schwartz M, Yoles E. RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest Ophthalmol Vis Sci 2000, 41:4169-74.
16. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001, 42:2849-55.
17. Wheeler LA, Lai R, Woldemussie E. From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury. Eur J Ophthalmol 1999, 9(1):S17-21. Suppl.
18. Wen R, Cheng T, Li Y, Cao W, Steinberg RH. Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci 1996, 16:5986-92.
19. Donello JE, Padillo EU, Webster ML, Wheeler LA, Gil DW. Alpha(2)-Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther 2001, 296:216-23.
20. Fazzone HE, Kupersmith MJ, Leibmann J. Does topical brimonidine tartrate help NAION?. Br J Ophthalmol 2003, 87:1193-4.
21. Wilhelm B, Ludtke H, Wilhelm H. Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial. Graefes Arch Clin Exp Ophthalmol 2006, 244:551-8.
22. Ding K, Scortegagna M, Seaman R, Birch DG, Garcia JA. Retinal disease in mice lacking hypoxia-inducible transcription factor-2alpha. Invest Ophthalmol Vis Sci 2005, 46:1010-16.
23. Sun Y, Jin K, Xie L. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 2003, 111:1843-51.
24. Wiesener MS, Turley H, Allen WE. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood 1998, 92:2260-8.
25. Salceda S, Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997, 272:22642-7.
26. Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L. Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci USA 1997, 94:5667-72.
27. Lee PJ, Jiang BH, Chin BY. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem 1997, 272:5375-81.
28. Garnier P, Demougeot C, Bertrand N, Prigent-Tessier A, Marie C, Beley A. Stress response to hypoxia in gerbil brain: HO-1 and Mn SOD expression and glial activation. Brain Res 2001, 893:301-9.
29. Dudzinski DM, Igarashi J, Greif D, Michel T. The regulation and pharmacology of endothelial nitric oxide synthase. Annu Rev Pharmacol Toxicol 2006, 46:235-76.
30. Beschorner R, Adjodah D, Schwab JM. Long-term expression of heme oxygenase-1 (HO-1, HSP-32) following focal cerebral infarctions and traumatic brain injury in humans. Acta Neuropathol 2000, 100:377-84.
31. Arai-Gaun S, Katai N, Kikuchi T, Kurokawa T, Ohta K, Yoshimura N. Heme oxygenase-1 induced in muller cells plays a protective role in retinal ischemia-reperfusion injury in rats. Invest Ophthalmol Vis Sci 2004, 45:4226-32.
32. McLean CW, Mirochnitchenko O, Claus CP, Noble-Haeusslein LJ, Ferriero DM. Overexpression of glutathione peroxidase protects immature murine neurons from oxidative stress. Dev Neurosci 2005, 27:169-75.
33. Chan PH, Kawase M, Murakami K. Overexpression of SOD1 in transgenic rats protects vulnerable neurons against ischemic damage after global cerebral ischemia and reperfusion. J Neurosci 1998, 18:8292-9.
34. Scortegagna M, Ding K, Oktay Y. Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice. Nat Genet 2003, 35:331-40.
35. Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 2001, 25:386-401.
36. Buckingham BP, Inman DM, Lambert W. Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma. J Neurosci 2008, 28:2735-44.
37. Danylkova NO, Alcala SR, Pomeranz HD, McLoon LK. Neuroprotective effects of brimonidine treatment in a rodent model of ischemic optic neuropathy. Exp Eye Res 2007, 84:293-301.
38. Wheeler LA, Woldemussie E. Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma. Eur J Ophthalmol 2001, 11(2):S30-5. Suppl.
39. Mayor-Torroglosa S, De la Villa P, Rodriguez ME. Ischemia results 3 months later in altered ERG, degeneration of inner layers, and deafferented tectum: neuroprotection with brimonidine. Invest Ophthalmol Vis Sci 2005, 46:3825-35.
40. Yoles E, Wheeler LA, Schwartz M. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci 1999, 40:65-73.
41. Mondal LK, Baidya KP, Bhattacharya B, Chatterjee PR, Bhaduri G. The efficacy of topical administration of brimonidine to reduce ischaemia in the very early stage of diabetic retinopathy in good controlled type-2 diabetes mellitus. J Indian Med Assoc 2004, 102:729-5.
42. Evans DW, Hosking SL, Gherghel D, Bartlett JD. Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection. Br J Ophthalmol 2003, 87:1463-5.
43. Tsai JC, Chang HW. Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study. J Ocul Pharmacol Ther 2005, 21:475-8.
44. Oshitari T, Dezawa M, Okada S. The role of c-fos in cell death and regeneration of retinal ganglion cells. Invest Ophthalmol Vis Sci 2002, 43:2442-9.
45. Fu R, Zhao ZQ, Zhao HY, Zhao JS, Zhu XL. Expression of heme oxygenase-1 protein and messenger RNA in permanent cerebral ischemia in rats. Neurol Res 2006, 28:38-45.
46. Tai SC, Robb GB, Marsden PA. Endothelial nitric oxide synthase: a new paradigm for gene regulation in the injured blood vessel. Arterioscler Thromb Vasc Biol 2004, 24:405-12.
47. Eto M, Barandier C, Rathgeb L. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ Res 2001, 89:583-90.
48. McQuillan LP, Leung GK, Marsden PA, Kostyk SK, Kourembanas S. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am J Physiol 1994, 267:H1921-7.
49. Le Cras TD, Xue C, Rengasamy A, Johns RA. Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung. Am J Physiol 1996, 270(1):L164-70. Pt 1
50. Arnet UA, McMillan A, Dinerman JL, Ballermann B, Lowenstein CJ. Regulation of endothelial nitric-oxide synthase during hypoxia. J Biol Chem 1996, 271:15069-73.
51. Renno RZ, Youssri AI, Michaud N, Gragoudas ES, Miller JW. Expression of pigment epithelium-derived factor in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2002, 43:1574-80.